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"WHENEVER you find that for a particular disease there are many remedies, you
may know that there is something doubtful about the action of these remedies, and
that none is particularly efficacious."
INTRODUCTION
We have come a long way since Mackenzie wrote these words in 1905, and yet
in one sense they are still true. It is not that the modern modes of treatment are of
doubtful value; all are effective, but the ideal treatment for hyperthyroidism still
eludes us. Neither do we have reliable methods of selecting the best treatment for
the individual patient. This could be arranged more rationally if it was possible to
predict which patients would undergo spontaneous remission without therapy and
which would suffer protracted and serious illness.
The aim of treatment is to reduce the secretion of the thyroid gland to a level
which supports normal metabolic processes, to prevent complications and to correct
those already present. Specific measures which reduce the secretion of the toxic
gland effectively are antithyroid drugs, subtotal thyroidectomy and radioactive
iodine. Opinions differ about their relative merits and no well-controlled com-
parisons of the three methods appear to have been made.
The purpose of this paper is to report the experience gained in the Metabolic
Unit of the Royal Victoria Hospital in treating patients with hyperthyroidism and
to make an appraisal of their advantages and disadvantages. Table I shows how
some of our patients have been managed over the last 14 years. All these have been
subject to special analysis and study. Some have had more than one form of treat-
ment. Antithyroid drugs and surgery have, of course, been continued since 1967,
although not analysed for the purpose of this presentation.
ANTITHYROID DRUG TREATMENT
Many different forms of medical treatment have been used over the years to
treat thyrotoxicosis but all have been superceded by the use of modem definitive
antithyroid drugs and beta-adrenoceptor blockade.
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* Based in part on a lecture delivered at the Royal College of Surgeons in London in 1970
and revised.TABLE I
Treatment of Hyperthyroidism and Methods Employed 1960-1973
Metabolic Unit, Royal Victoria Hospital, Belfast
Medical- RAI- RAI-small
antithyroid Surgical conventional dosagewith Propranolol
drugs dosage propranolol alone
1960-67 153 128
1961-66 - 254 -
1968-73 - - 247
1970-71 - 25
Antithyroid Drugs
These are of two types: (1) those which interfere with the synthesis of thyroid
hormones (methyl and propyl thiouracil, methimazole and carbimazole, and (2)
those which inhibit the trapping of iodide by the thyroid gland (perchlorate).
Definitive treatment of hyperthyroidism with antithyroid drugs is undertaken in the
hope t;hat the disease will undergo spontaneous remission, or that the gland will
alter in such a way that the hyperthyroidism will not recur when therapy is stopped.
Earlier writers on the thyroid (see Wilson 1966) claimed remission in nearly a third
of their patients. Recent knowledge of the natural course of thyrotoxicosis is un-
known since few patients are permitted to go untreated. Perhaps the easiest way of
studying the natural history of the disease is to block its peripheral manifestations
with propranolol. Results achieved using this method (see later) confirm the view
that remissions of the order of 30 to 40 per cent probably occur naturally. On the
other hand, in a study of 50 untreated patients (in terms of specific antithyroid
therapy) with fully developed exophthalmic goitre, Kessel and his colleagues (1923)
found only one patient in full remission at the end of a year's observation, although
many had improved with non-specific measures. It must be accepted then that, for
the present, we do not know how antithyroid drugs "cure" the patient in whom a
remission has been obtained. A possibility is that antithyroid drugs induce remis-
sions by virtue of reducing the level of thyroid hormone which, in turn, may have
an effect on the production of LATS and LATS protector. In other words, the
return of the euthyroid state may reduce the tendency of the body to synthesiz,e
antibody directed against the thyroid gland (McKenzie 1967). Others (Alexander
et al 1965; Harden et al 1966) have shown that depletion of the body's store of
iodine increases the likelihood of achieving a remission. However, the remission
rates achieved by us with antithyroid drugs and propranolol alone (see below) are
not much better than the chance of obtaining a natural remission. This must make
us ask: Are these drugs doing anything more than making the patient comfortable
while a natural remission takes place?
The response of a series of 153 patients treated with carbimazole is shown in
Table II. All had continuous treatment for at least 18 months and more than half
had had it continued for over two years. The results show that only 43 per cent
achieved a remission and that 51 per cent relapsed and required other therapy.
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Antithyroid Treatment (Carbimazole) for Hyperthyroidism
(153 patients) 1960-67
Clinicalstatus Number Percentage
Euthyroid (follow-up j.-8 years) 64 43
Remaining on therapy at time of review 6 4
Untraced 4 2
Relapsed-treated surgically 75 49
..51.
Relapsed-treated with RAI 4 2
Total 153 100
Indeed, a remission rate of 43 per cent may be optimistic because a few patients
were observed for less than 12 months after the withdrawal of treatment. Since the
majority of relapses occur within a year of this the relapse rate might have been
higher if all had been observed for a minimum period of a year.
TABLE III
Incidence of Remission achieved with Antithyroid Drug Treatment
(from Astwood, E. B. 1967)*
No. of Yearsafter Remission
Authors patients treatment (percenrtage)
Solomon et al 101 4-10 55-70
MoCullagh and Cassidy 60 4-6 66
Douglas and McKenzie 187 ?-5 45
Manson 70 >1 71
Goodwin et al 94 *-1 41
Aspenstrom 120 >1 70
Trotter 157 10 45
Wilcox 152 1-12 72
Revens and Rosenbaum 167 4-19 57
Hershman etal 176 6-20 54
Metabolic Unit, R.V.H. 153 j-8 43
Total 1,437 56
*Reproduced by permission of Churchill Livingstone
The reported remission rate achieved by other workers in the field (Astwood
1967) is shown in Table III. Such reports are difficult to compare with each other.
However, if one takes a crude average, the overall rate of remission is over 50 per
cent. This is probably too high and the best that can be expected for medical treat-
75ment will be between 40 and 50 per cent. This means that definitive treatment with
antithyroid drugs will often be ineffective, unless the patient and doctor are pre-
pared to continue treatment for an almost indefinite period.
Recently it has been fashionable to try and forecast those patients who are likely
to respond to a course of medical treatment from those who will not. Empirical
criteria include a small smooth gland, young patient, short history and a reduction
in the size of thegoitre during treatment, but none are very reliable. Another method
involves the identification of patients in whom thyroid suppressibility returns during
treatment (Alexander et al 1966). The test is useful in distinguishing between hyper-
thyroid patients and euthyroid patients with a high 1311 neck uptake. Failure of the
radioactive iodine uptake (RAIU) by the thyroid to be suppressed by thyroid hor-
mones (eg, triiodothyronine 100 mg daily for seven days) is characteristic of hyper-
thyroidism (Werner et al 1952; Werner 1955). A positive response (suppressibility)
is defined as a fall of 50 per cent or more of the pre-treatment RAIU or a 20-minute
uptake of less than 8 per cent (Alexander et al 1967). The test has been used to try
and separate patients who will obtain a prolonged remission with antithyroid drugs
from those who will not. Lack of suppressibility is said to be followed by relapse
and the return of thyroid suppression during treatment means that a remission will
follow the withdrawal of the drug. Proponents of this view (Alexander et al 1967)
believe that if thyroid function remains unsuppressible at the end of six months'
medical therapy it should be abandoned in favour of subtotal thyroidectomy or
radioactive iodine treatment. Unfortunately, the test has not proved to be sufficiently
reliable upon which to base a programme of treatment, for it does not indicate
clearly those patients who will eventually relapse or remain in remission (Lowry
et al 1971; Table IV) and for these reasons it has largely been abandoned. Similar
hopes were expressed for the TRH test, which correlates well with the T3 suppres-
sion test (Ormston et al 1973), but experience has shown it to be no more reliable.
TABLE IV
Thyroid Suppressibility in Relationship to Remission and Relapse
in Hyperthyroid Patients treated with Antithyroid Drugs*
Clinical status 2 years Suppressed Non-suppressed
aftercompletionof treatment Number Percentage Number Percentage
Remission 35 (55o/%) 20 57.1 15 42.9
Relapse 29 (45%/0) 8 27.6 21 72.4
Total 65 28 43.8 36 56.2
*Lowry et al (1971)
Despite the drawbacks mentioned, antithyroid drugs play an important part in
the overall management of many thyrotoxic patients. They are helpful in the pre-
paration of patients for surgery and have a place in the treatment of hyperthyroid-
ism in special circumstances; for example, in pregnancy, childhood, for those wish-
76ing to avoid an operation and for the young patient with mild symptoms and a small
smooth gland. Toxic effects of carbimazole are rare and mostly mild and were noted
in three of the 153 patients described; an incidence of under 2 per cent. The advant-
ages of antithyroid drug treatment for hyperthyroidism are summarised in Table V.
TABLE V
Antithyroid Drug Treatment for Hyperthyraidism
Advantages
1. No damage is done to the thyroid gland.
2. No irreversible changes are induced.
3. Lasting myxoedema does not occur.
4. Hyperthyroidism can be corrected uniformly in a short time.
Disadvantages
1. High incidence of relapse of hyperthyroidism after treatment.
2. Inconvenience of frequent and prolonged (1-2 years) attendance at hospital
or health centre.
3. Small incidence of toxic side-effects.
4. Goitre does not diminish in size.
5. Few physicians attain sufficient expertise in their administration.
Iodine and liodides
Iodide increases the storage of colloid in the thyrotoxic gland and reduces the
height of the epithelial cells. It thus induces the changes characteristic of involution,
diminishes the vascularity of the gland and reduces thyroid hormone synthesis and
release. The effect is transient, however, so that iodides have no place in the treat-
ment of hyperthyroidism, apart from the preparation of patients for thyroidectomy
and in the management of a thyrotoxic crisis (Havard 1974).
Sympathetic antagonists
Many of the clinical features of hyperthyroidism resemble the effects of increased
activity of the sympathetic nervous system and two types of sympathetic antagonists
are helpful in the relief of symptoms and signs. Drugs such as reserpine and
guanethidine, which deplete the tissues of their catecholamine content, improve
symptoms without affecting the concentration of the circulating thyroid hormones.
However, their delayed action and side effects have precluded their general
use. More effective in controlling the heart rate and some of the peripheral
manifestations of thyrotoxicosis is the beta-adrenoceptor blocking drug pro-
pranolol. Since propranolol does not influence thyroid activity (Hadden et al
1969) it can be given in combination with radioactive iodine or as an adjunct
to antithyroid medication. It has been used successfully alone or with iodine
in preparing paltients for thyroidectomy (Vinik et al 1968; Pimstone and Joffe 1970;
Lee et al 1973; Michie et al 1974). Propranolol has greatly simplified preoperative
management. The peripheral manifestations of the disease are brought under con-
77trol quickly and the patient's apprehension of operation is rapidly allayed. Those
with mild or moderate disease are ready for operation in 10 to 14 days when given
iodine and propranolol together, while those with severe hyperthyroidism, given
antithyroid drugs simultaneously, are ready in three or four weeks. Propranolol is
given orally in a dose of 40 mg six-hourly during the period of preparation and for
several days after operation. If it is withdrawn prematurely, at or before surgery,
rebound tachycardia or cardiac arrhythmia may develop and be mistaken for a
thyroid crisis. Some surgeons (Lee et al 1973; Michie et al 1974) omit iodine pre-
operatively and depend solely on propranolol for the preparation of their patients.
lit remains to be seen whether other thyroid surgeons will follow suit. Iodine is so
safe, cheap and effective in reducing the activity of the hyperthyroid that it seems
unwise to abandon it altogether.
Propranolol alone in the management of hyperthyroidism
With increasing experience of the successful management of thyrotoxicosis using
smaller and smaller doses of RAI and propranolol (see later) it seemed logical to
try the effect of propranolol alone in treating the milder cases. Pimstone and others
(1969) suggested that this might be an acceptable form of definitive treatment.
Accordingly, 25 selected patients have been given 160 mg of propranolol daily for
up to one year as the sole method of treatment. The results are shown in Table VI
TABLE VI
Treatment of Hyperthyroidism with Propranolol Alone
Number of patients treated 25
Euthyroid at 1 year 10 (40%)
Remaining thyrotoxic at 1 year and
requiring additional treatment
(RAI, antithyroid drugs or surgery) 12 (48%)
Withdrawn from trial before 1 year
(miscellaneous reasons) 3 (12%)
Total 25
(Lowe et al 1975). Those who responded (40 per cent) became euthyroid between
two and nine months after commencing treatment. Since propranolol does not
affect the intrinsic function of the thyroid it is likely that these are naturally
occurring remissions of the disease process to which allusion has been made
already. It may or may not be significant that the remission rates for antithyroid
drug treatment and propranolol are so close. No difference could be found clinically
or biochemically between those who responded to propranolol and those who did
not. Ten euthyroid patients have now been followed for up to four years. Two have
subsequently relapsed after being euthyroid for three and two years respectively.
In the remaining eight patients the TRH test was positive in two and negative
(unsuppressible) in six 18 months after they went into remission. Unfortunately,
78propranolol alone cannot be recommended as a definitive form of antithyroid
treatment because it is impossible to select prospectively patients who are likely
to respond; a view supported by McLarty and others (1973).
Surgical treatment
Subtotal thyroidectomy has a long and honoured place in the management of
hyperthyroidism since the operation was introduced towards the end of last century
and perfected by Sir Thomas Dunhill in the first decade of this century. The results
achieved in a series of 128 patients treated surgically (1960-67) are shown in
Table VI.
TABLE VII
Hyperthyroid Patients Treated Surgically 1960-67
Subtotal thyroidectomy-
Subtotal thyroidectomy- afterfailed
Clinical All cases (128) initial treatment (53) medicaltreatment (75)
status Number Percntage Number Percentage Number Percentage
Euthyroid 108 84.3 41 77.3 67 89.4
Hypothyroid 12 9.4 7 13.3 5 6.6
Relapsed 8 6.3 5 9.4 3 4.0
Dead 0 0 0 0 0 0
Thyroidectomy was performed as first treatment in 53 patients and as second
treatment in a further 75 who had relapsed after antithyroid drug therapy (Table
VIi). It is of interest that slightly better results appear to have been achieved for
those who relapsed after antithyroid drugs than for those whom suirgery had been
selected as initial treatment. However, the numbers are too small from which to
draw valid conclusions. Thyroidectomy is equally successful in Graves' disease and
toxic nodular goitre. Unilateral lobectomy for the solitary toxic adenoma ("hot
nodule") removes the pathological lesion and allows the normal, but suppressed,
thyroid tissue to recover.
Complications of surgery in this series are listed in Table VIII. Most are not
serious but the morbidity associated with the operation still gives cause for concern.
Hypocalcaemia occurs frequently enough for all patients to be screened carefully
for three months after thyroidectomy. It has been suggested that "partial" or
"latent" hypoparathyroidism may sometimes follow thyroidectomy and cause vague
symptoms, which can be relieved by calcium supplements (Fourman 1967). This
view has not received general support (Billis and Montgomery 1967; Stowers et al
1967). Deficiency of calcitonin as the result of thyroidectomy does not appear to
affect calcium homeostasis to any extent. McIntyre (1969) has suggested that this
may be due to extra thyroidal sources of calcitonin. Conversely, hypocalcaemia is
not found in the presence of medullary cell carcinomas of the thyroid secreting
calcitonin in excess (Montgomery and Welbourn 1975).
79TABLE VIII
Complications of Subtotal Thyroidectomy for Hyperthyraidism
(128 cases)
Number Percentage
1. HAEMORRHAGE
(a) Requiring surgery 3 2
(b) Extensive bruising 5 4
2. SEROSANGUINEOUS EFFUSION
(a) Requiring aspiration 1 1
3. CHEST INFECTION OR PULMONARY COLLAPSE 7 5
4. WOUND INFECrION (serious) 4 3
5. RECURRENT LARYNGEAL NERVE PALSY
'(a) Bilateral 0 0
(b) Unilateral - Temporary 10 8
Permanent 0 0
6. TETANY(Hypoparathyroidism)
(a) Temporary 7 5
(b) Permanent (requiring continuous therapy) 4 3
7. HYPOTHYROLDISM
(a) Temporary 2 2
(b) Permanent (requiring continuous therapy) 12 9
8. UNSATISFACrORY ISCAR
(a) Fibrosis 0 0
(b) Keloid 3 2
From these results and essentially similar figures published in several other
British surveys (Wade 1960; Riddell 1962, 1970; Green and Wilson 1964; McNeill
and Thompson 1968) it may be concluded that subtotal thyroidectomy offers the
patient a better than 80 per cent chance of a remission and that the incidence of
major surgical complications, such as recurrent laryngeal nerve damage or per-
manent hypoparathyroidism, while not great, still occur and must continue to
challenge thyroid surgeons to produce even better results. The 9 per cent incidence
of hypothyroidism might increase with a longer period of observation. On the other
hand, we were impressed with the rapidity with which hypothyroidism developed
in this group. Most were diagnosed within 12 months of operation. The early onset
of hypothyroidism has been confirmed by Olsen et al (1970)i and 'Michie et al
(1972). All but one of the latter's patients who became hypothyroid did so within
the year following thyroidectomy. They concluded that if a sufficiently high degree
of suspicion of hypothyroidism is maintained during the early postoperative months
the late diagnosis of hypothyroidism is rare. In Britain, the incidence of hypo-
thyroidism afterithyroidectomy has ranged from 3.3 to 49 per cent (Riddell 1962;
Michie et al 1972). In America, for example, a figure quoted for the development
80of hypothyroidism following surgery for Graves' disease is 42.8 per cent (Beahrs
and Sakulsky 1968) and Olsen and his colleagues (1970) quote an incidence of 25
to 50 per cent.
The causes of postoperative hypothyroidism are not fully understood. Neither
the age or sex of the patient, the size of the goitre or the amount and duration of
preoperative antithyroid drug therapy appear to be involved (Michie et al 1972).
On the other hand, Michie found that the size of the thyroid remnant was the most
significant aetiological factor. When a policy of increasing the size of the thyroid
remnant was adopted the hypothyroid rate fell although it was not abolished.
However, the policy of leaving a larger remnant increases the risk of ,recurrence
of the hyperthyroidism. Wilson (1967) observed that with the removal of a smaller
amount of thyroid there is a diminished incidence of hypo!thyroidism and a higher
recurrence rate, while with the more radical excision the reverse holds.
Variations in iodine intake and surgical technique may reflect the differing
ipcidence of postoperative hypothyroidism in certain parts of the world. The level
of thyroid antibodies in serum appears to be important and where these are high
the incidence may be of the order of 25 per cent or more (Irvine and Stewart 1967;
van Welsum et al 1974). The former authors suggest that a high level of circulating
thyroid autoantibodies is a relative contraindication of thyroideotomy and that if
it is performed the patient should be kept under regular supervision. Possibly in
these cases the operation should be less radical than usual. In, contrast to surgery,
serological tests seem to be of little value in predicting the development of hypo-
thyroidism in patients treated with RAT or of any prognostic value in determining
the outcome of the patient's response to antithyroid drug therapy.
Radioactive iodine treatment (RAJT)
Radioactive iodine has been in use since 1941 but it was not until the early
1950's that large numbers of patients received this form of therapy. RAIT although
much slower in correcting hyperthyroidism (8 to 12 weeks or longer) than subtotal
thyroidectomy or antithyroid drugs seemed, at first, to be an ideal method of
treatment. For the patient it is the most convenient as it involves only a drink of
tasteless water. However, there were some initial difficulties because no satisfactory
way of estimating the correct dose of RAI, in relation to size, activity or nodularity
of the thyroid gland could be evolved. Too small a dose did not cure the hyper-
thyroidism, whereas too large a dose caused early and permanent hypothyroidism.
The most serious objection to RAIT, however, has become apparent only with the
passage of time. In the 1960's, reports of a disturbingly high and progressive
incidence of hypothyroidism began to appear from Scandinavia, Great Britain,
America and elsewhere. These showed a relentless increase in the incidence of
hypothyroidism each year after treatment which reaches a level of about fifty per
cent or more at 10 years (Beiling and Eindhorn 1961; Green and Wilson 1964;
Nofal et al 1966).
From 1961 to 1966, 254 patients were treated in the Metabolic Unit (Bhatia
et al 1968) using conventional doses of RAI (150 ptCi/g thyroid tissue). Adequate
information about their thyroid function was obtained in over 98 per cent sub-
sequently, and 232 were re-examined in 1967 and 1968 (Table IX). For the group
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Therapeutic Radioactive Iodine 1961-66
Thyroid Status at Review (1967-68)
Mean
Year offirst dose Numberofpatients Euthyroid Hypothyroid
treatment mCi Treated Reviewed Number Percentage Number Percernage
1961 8.2 36 31 13 42 16 51
1962 8.6 62 55 24 43 18 33
1963 8.1 40 35 14 40 16 45
1964 5.1 43 39 22 56 9 23
1965 4.2 48 48 22 45 7 15
1966 4.8 25 24 14 58 4 16
Total 254* 232 109 47 70 30
* 15R natients had1 nn nreviAnii treatment 1-0 sJawtlVILLO IlLUW ILLY F%VLUUO tLWllUWllL-t
81 patients had failed antithyroid treatment.
8 patients had a previous subtotal thyroidectomy.
7 patients had both drug treatment and subtotal thyroidectomy.
as a whole the remission rate, i.e., the achievement of euthyroidism was 47 per cent,
while 30 per cent were hypothyroid. However, the longer patients were observed
the greater was the incidence of hypothyroidism. For example, 51 per cent of the
original 36 patients treated in 1961 were hypothyroid six years later. From 1964
onwards, the dose of RAI was reduced substantially and the incidence of hypo-
thyroidism diminished slightly. Nevertheless, 23 per cent of the 1964 group were
hypothyroid in three years. If to this figure is added a yearly cumulative incidence
of about 4 per cent of hypothyroidism, which these results suggest, this 23 per cent
becomes 35 per cent at six years; an incidence which is still very discouraging.
TABLE X
Effect of Age at First Treatment on Subsequent Incidence of Hypothyroidism
Totalpercentage
Agegroup Totalpatients Mean dose hypothyroid
(years) treated 1961-66 ofRAI(mCi) atreview
40-49 89 6.57 38.2
50-59 92 6.70 27.1
60+ 73 6.24 15.1
The effect of age on the development of hypothyroidism is shown in Table X.
The youngest age group had the highest incidence of hypothyroidism regardless of
the year of treatment. Differences in the size of the goitre, dosage and turnover
rates of RAI do not appear to explain this difference and it is probable that the
"younger" the thyroid gland is the more sensitive is it to the effects of ionizing
82irradiation. The incidence of hypothyroidism in those who had previously received
a course of antithyroid drugs was 26 per cent, less than for the whole group but
not statistically significant. For those who had a thyroidectomy previously the rate
soared to 62 per cent (five out of eight subjects).
It must be clear to all that the late results of RAIT are most disappointing
Patients require regular follow-up for sooner or later many will require permanent
treatment with thyroxine. For these reasons some clinicians felt that such results
could not be tolerated and have sought methods that would exploit the advantages
of RAIT (using smaller doses) while at the same time diminishing the risk of
hypothyroidism. These carry the risk, however, of incomplete control of the disease
and usually necessitate the administration of an antithyroid drug as well (Smith
and Wilson 1967; Smith et al 1970; Rapoport et al 1973). While these methods
reduce substantially the risk of hypothyroidism developing (a reduction from
30 per cent to 8 per cent at two years according to Smith et al 1970), the long
period of antithyroid drug treatment makes it less acceptable from the patient's
point of view. It can be argued that if RAIT is to be extended over several years
using antithyroid drugs, it might be preferable to accept the incidence of hypo-
thyroidism with conventional RAIT alone and administer thyroxine if and when
it is needed.
In 1968, we reduced the treatment does of RAI by about half from that employed
earlier, to a level of about 70 jpCi/g thyroid tissue. With an average size goitre
this meant a therapeutic dose of about 2.5 mCi and this amount was prescribed
routinely for all patients. Subsequently the dose was reduced by a further 50 per
cent to 1.25 mCi. At the same time 160 mg of propranolol was given daily to
control symptoms until the intrinsic thyroid abnormality was brought under control.
Table XI summarises the results obtained with this form of combined therapy in
patients given a single dose of RAIT (those given two or more doses have been
omitted for the purpose of this presentation). The incidence of hypothyroidism at
one year with 2.5 mCi is not far short of that achieved with larger doses but at four
years it is much less. For the 1.25 mCi dose the hypothyroid rate is very much less
and, although the number of patients achieving euthyroidism at one year is slightly
fewer the difference is not pronounced.
The management of patients who have not responded to treatment with a small
dose of RAIT at three or four months poses a number of problems. Although a
few may become euthyroid over the succeeding months, the majority are likely to
TABLE XI
Small Dose RAIT 1968-73
No. of patients
Dose RAI(mCi) given a Euthyroidi(%) Hypothyroid(%)
single dose 1 year 4 years 1 year 4 years
2.5 63 41 43 13 17
1.25 32 35 39 0 3
83remain hyperthyroid, although protected, to some extent, from the effects of the
thyroid toxicity by propranolol. However, adrenergic blockade is unlikely to prevent
all the metabolic consequences of protracted hyperthyroidism-for example, the
possilbility of progressive osteoporosis (McLarty et al 1973). For these reasons, a
second dose of 2.5 or 1.25 mCi of RAI is given at three or four months to non-
responders. Third or even fourth supplemental doses may be required in an attempt
to titrate the amount of RAI required to provide the optimum dose to control
thyroid toxicity without inducing hypothyroidism. As might be expected, more
(55 per cent) of the 1.25 mCi group than the 2.5 mCi group (38 per cent) required
additional doses of RAI to achieve euthyroidism. The long-term effectiveness of
this method remains to be worked out fully and will be the subject of a subsequent
report but the early results are encouraging. Nevertheless, the criticism levelled at
the combined regime of small dose RAIT with antithyroid drugs can be made
equally against RAI and propranolol. The only point of difference is that the
control of treatment is easier with the latter, for achievement of euthyroidism is
specifically related to the RAI, whereas in the former it may be due to either the
RAI or antithyroid drug.
SUMMARY AND CONCLUSIONS
This review has attempted to show what can be achieved with ithe available
methods of treating hyperthyroidism. None alter the underlying cause of the
disease; a possible exception being the removal of a single toxic nodule. Anti-
thyroid drugs and propranolol suppress thyroid hyperfunction or its peripheral
manifestations; a lasting cure probably depending on a natural remission which we
are powerless to influence. Surgery and radioactive iodine destroy part of the gland
and the eventual outcome depends on the balance between the amount of tissue
destroyed and the function of the remainder. Until more is known about the funda-
mental mechanism of hyperthyroidism so that it can be prevented or its causal
factors removed, we must apply existing methods in the most efficient way.
Effective treatment can nearly always be provided and the advantages and dis-
advantages of each method are set forth below: -
Antithyroid drugs
1. Limited value as definitive treatment.
2. Useful in special circumstances.
3. Morbidity minimal and reversible.
4. Remission in selected cases between 40 and 50 per cent.
Surgery
1. Remission rate between 80 and 90 per cent.
2. Hypothyroidism variable but often considerable; high antibody tiltre significant.
3. Morbidity still important and serious for the patient.
Radioactive iodine
1. Remission rate of just under 50 per cenit.
2. High cumulative incidence of hypothyroidism.
3. Of value in controlling persistent hyperthyroidism.
84All these factors must be considered in relation to the age, clinical findings,
nature of the goitre and the patient's emotional make-up and responsibilities. There
are many in whom the choice of treatment is not easy. Problems arise, for instance,
when the gland is of moderate size or causing minimal compression of the trachea
or when the patient is a few years under the age of 40. A planned policy for treat-
ment must be selected from the start. Where the diagnosis is in doubt, symptomatic
TABLE XII
*
Treatment
Typeof GoitreandClinical Features recommended
I. Diffuse Goitre
1. Under40 years
(a) Small gland and mild or moderatetoxicity
(b) Largegland and moderate or severe toxicity
2. Over 40 years
II. Nodular Goitre
1. Under 40 years
2. Over 40 years
(a) Small gland without obstruction
(b) Large gland with obstruction
III. Recurrent Thyrotoxicosis
1. After antithyroid drugs
(a) Under 40 years
(b) Over 40 years
2. After operation
(a) Under 40 years
(b) Over 40 years
(c) Large obstructive goitre at any age
3. After radioactive iodine
IV. Special Circumstances
1. Childhood
2. Pregnancy
3. Neonatal thyrotoxicosis
4. Infirmity (heart failure, old age,
intercurrent disease, etc)
5. Hyperophthalmopathic Graves' disease
6. Solitary toxic adenoma
7. Thyrotoxic crisis
Antithyroid drugs
Subtotal thyroidectomy
Radioactive iodine
Subtotal thyroidectomy
Radioactive iodine
Subtotal thyroidectomy
Subtotal thyroidectomy
Radioactive iodine
Antithyroid drugs
Radioactive iodine
Subtotal thyroidectomy
Radioactive iodine
Antithyroid drugs
Antithyroid drugs or
subtotal thyroidectomy
Antithyroid drugs
Radioactive iodine
Antithyroid drugs until
eyes stabilized and
special measures
Partial thyroidectomy
Special measures
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*Reproduced by permission of the publishers, Arnold, London.control of the hyperthyroidism can be achieved with propranolol, while investiga-
tion proceeds unhampered by treatment. The best'results are achieved by the close
collaboration of physicians and surgeons and the provision of a careful follow-up
system.
Table XII summarises the general policy for treatment hypenthyroidism in the
Metabolic Unit, Royal Victoria Hospital, which has evolved over the last decade.
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BOOK REVIEWS
OBSTETRICS ILLUSTRATED. By M. M. Garry, A. D. T. Govan, C. Hodge
and R. Callender. Second Edition. (Pp. 538. Illustrated. £3.75). Edinburgh
and London: Churchill Livingstone. 1974.
THE second edition of this book, coming only five years after the first (which went to
three reprintings), must speak of its popularity. The combination of line drawings and simple
text produces a method for easy assimilation by the ever-pressed medical student. The rapid
changes in many aspects of the specialty have been coped with by extensive rewriting of
chapters dealing with fetal monitoring, early diagnosis of immaturity and dysmaturity,
induction techniques and planned labour and delivery; the chapter relating to the newborn
infant is particularly well presented. The remaining subject matter is covered adequately
having sections on physiology and anatomy as well as dealing with the most common, and
a good few not so common, pathological states of pregnancy. One obvious error appears on
page 186 relating to the estimation of H.S.A.P. The authors rightly point out that this test
has now been shown to have little clinical use as it is not sufficiently discriminating;
however the estimation of the enzyme is not carried out on a sample of amniotic fluid.
This book (500 pages) is very reasonably priced at £3.75 and I would recommend it to the
undergraduate.
W.T.
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